Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated ...
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results